Forgot Password?
Return to Course Listing

CME: Psoriatic Arthritis: Therapeutic Updates and Optimizing Treatment


Activity Description / Statement of Need:

In this online CME self-learning program:


Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may be associated with permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Though rare in the otherwise healthy population, it is a common comorbidity of patients with psoriasis, affecting them in about 6% to 10% of cases overall and in about 20%-40% of those with extensive skin involvement. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible.


There have been a wide array of advances in care in the area of pharmacotherapeutic options, including both presently approved (for PsA) therapies – some for short-term, symptomatic management– as well as more novel, potential ones on the horizon. Helping the clinician discern the role of each of agent – present and future – merits continuing healthcare professional education.





Faculty introduction, disclosures

Introduction content: cursory refresher and review of PsA

  • Epidemiology: statistics by severity
  • Clinical features, presentation, pathophysiology, and disease progression

Treatment of PsA

  • Society guidance: ACR, American Academy of Dermatology, EULAR, GRAPPA, BSR, BHPR
  • Clinical trial findings and guideline updates
  • Present pharmacotherapy: orals, topicals, biologicals, injectable corticotropin gel
  • Minimizing adverse effects
  • An increased focus on comorbidities
  • Other clinical pearls
  • Emerging and future therapies
  • Optimizing patients’ adherence to their therapy
  • The additional opportunities for the healthcare professional in managing treatment expectations in PsA
  • Patient case(s)

Summary, conclusions, and best practice recap

Target Audience:


Healthcare professionals specializing in dermatology, rheumatology, internal medicine, or those who otherwise may encounter commonly encounter patients with PsA.

This program is supported by an educational grant from Mallinckrodt.


This activity is available to learners free of charge.

Release Date: September 28, 2016 -- Expiration Date: September 28, 2018

Faculty: Robin Dore, MD


Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology of PsA such that it might inform treatment mechanisms.
  • Describe strengths of different professional organizations´┐Ż guidance in PsA and treatment.
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of PsA and apply them to patient cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient with PsA to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
  • Describe the challenges and barriers to care associated with treating patients with PsA.



Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty Disclosure: Dr. Robin Dore, MD, Clinical Professor of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA discloses that she has received grant/research funding from, is on a speaker's bureau, and is a consultant for: Abbvie, Celgene, Amgen, Lilly, Pfizer, Takeda, UCB, and BMS.


Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.


Commercial Support Disclosure: This program is supported by an educational grant from Mallinckrodt.

This activity is available to learners free of charge.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Rheumatoid Arthritis (RA): Optimizing Pharmacotherapeutic Management Strategies

Psoriasis: Best Practices, Barriers to Care, and Emerging Therapies in Medication Management

Systemic lupus erythematosus (SLE): therapeutic updates and optimizing treatment

Rheumatoid Arthritis (RA) : Therapeutic Updates and Optimizing Treatment